CervoMed Strengthens Leadership with Technical Operations Hire to Advance Neflamapimod Toward Phase 3

CervoMed Inc. (NASDAQ:CRVO) is one of the best-performing NASDAQ stocks according to analysts. On June 10, CervoMed announced a significant addition to its senior leadership team. Dr. Marco Verwijs, PhD, joined CervoMed in June this year as Executive Vice President, Technical Operations. The strategic hire is intended to support the company’s Chemistry, Manufacturing, and Controls/CMC division.

This hire will also support the advancement of neflamapimod through Phase 3 testing and preparation for commercial manufacturing, as Dr. Verwijs brings extensive experience in drug development, spanning from the pre-clinical stage through NDA submissions and commercial launch. Before joining CervoMed, he served as CTO at Adipo Therapeutics. His expertise includes a particular focus on drug product and process development, scale-up, and validation, as well as overseeing supply chain and quality assurance.

Neflamapimod is an investigational and orally administered small-molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. It is being developed to potentially treat synaptic dysfunction, which is a reversible aspect of the neurodegenerative processes underlying DLB and other major neurological disorders.

CervoMed Inc. (NASDAQ:CRVO) is a clinical-stage biotechnology company that develops and commercializes treatments for age-related neurologic disorders.

While we acknowledge the potential of CRVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.